NCT04270942 - At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

January 22, 2024

Study Completion Date

January 22, 2024

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

teplizumab 1 mg/mL

"Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody).~Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily"

Trial Locations (8)

32610

Clinical Site, Gainesville

University of Florida Site Number : 02, Gainesville

37232

Clinical Site, Nashville

Vanderbilt Univerity Medical Center Site Number : 03, Nashville

80045

Barbara Davis Center for Diabetes Site Number : 04, Aurora

Clinical Site, Aurora

06511

Yale University School of Medicine Site Number : 01, New Haven

06519

Clinical Site, New Haven

All Listed Sponsors

lead

Provention Bio, a Sanofi Company

INDUSTRY